Reporter brief
Metformin safety and neuroprotection in older adults with MS: 9-month RCT.
What happened
A randomized, placebo-controlled pilot study examined metformin extended-release (1500 mg/day) as monotherapy or add-on treatment in older people with multiple sclerosis. The study assessed safety, tolerability, and neuroprotective effects measured by brain MRI over 9 months. No results or findings are reported in this abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Older people with multiple sclerosis (MS)
- Design
- Rct
- Sample
- —
- Journal
- State University of New York at Buffalo
- Published
- Nov 21, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.